Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a development-stage biopharmaceutical company whose news flow centers on the clinical and corporate progress of its pain and neuropathy programs. The company regularly issues updates on Halneuron®, its lead non-opioid NaV 1.7 analgesic in Phase 2b development for chemotherapy-induced neuropathic pain (CINP), as well as on SP16 IV, its LRP1 agonist candidate with potential to treat neuropathy and repair nerve damage following chemotherapy.
News items for DWTX commonly include interim clinical trial readouts, enrollment milestones and study design details for the HALT-CINP Phase 2b trial, where Dogwood reports on safety, tolerability and pain improvement data compared with placebo. The company also provides announcements on regulatory designations, such as FDA fast track status for Halneuron® in CINP, and on preclinical findings that describe mechanisms like NaV 1.7 modulation and LRP1-mediated anti-inflammatory and neural repair activity.
Investors following Dogwood’s news can expect coverage of financing transactions, including registered direct offerings, concurrent private placements and equity incentive plan approvals disclosed through press releases and Form 8-K filings. The company’s communications also highlight licensing deals, such as the exclusive, royalty-free global license for SP16 IV, and describe how these transactions expand the research pipeline in cancer-related pain and chemotherapy-induced neuropathy.
Additional news categories include participation in investor conferences and scientific meetings, where Dogwood’s management discusses the Halneuron® pain research program, synthetic manufacturing advances and the antiviral platform involving IMC-1 and IMC-2 for fibromyalgia and Long-COVID. For readers interested in DWTX, this news page aggregates these clinical, regulatory, financial and partnership developments in one place for ongoing reference.
Dogwood Therapeutics (NASDAQ: DWTX) has initiated dosing in its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). The drug targets the NaV 1.7 sodium channel and represents a potential opioid-free, addiction-free treatment for the $1.5B worldwide CINP market.
Halneuron® has demonstrated promising results in previous trials, showing statistically significant reduction in cancer-related pain with an acceptable safety profile. The drug has been tested in over 700 patients across Phase 1 and 2 studies, showing no addiction potential.
The company aims to recruit 100 CINP patients by Q4 2025, with an interim analysis planned for the same quarter. The adaptive trial design allows for potential study modifications to optimize outcomes.
Dogwood Therapeutics (NASDAQ: DWTX) has announced a registered direct offering of 578,950 shares of common stock priced at $8.26 per share, aiming to raise approximately $4.8 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close on March 14, 2025.
The proceeds will be used to advance the clinical development of Halneuron®, the company's lead candidate for non-opioid pain treatment, and for working capital purposes. Combined with existing cash, this financing will fund operations through Q1 2026. The company plans to announce interim data from its ongoing Halneuron® Phase 2b trial in chemotherapy-induced neuropathic pain (CINP) in Q4 2025.
Maxim Group is serving as the sole placement agent for the offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
Dogwood Therapeutics (Nasdaq: DWTX) announces the conversion of $19.5 million in debt to equity, as its largest shareholder CK Life Sciences Int'l converts outstanding loan amounts into 284.2638 shares of preferred equity. This strategic move eliminates all existing debt from Dogwood's balance sheet.
The conversion demonstrates CKLS's confidence in Halneuron®, a first-in-class NaV 1.7 specific voltage gated sodium channel inhibitor being developed for chronic and acute pain treatment. The financing, initially provided in October 2024, ensures capital for patient recruitment through a planned interim assessment of the ongoing Phase 2b CINP (chemotherapy-induced neuropathic pain) trial in Q4 2025.
Each preferred share will be convertible into 10,000 common shares, subject to stockholder and Nasdaq approval. Notably, Halneuron® has shown promising results in previous trials, demonstrating significant reduction in cancer-related pain across 700+ patients with no addiction potential.
Dogwood Therapeutics (NASDAQ: DWTX) announced plans to begin patient dosing in Q1 2025 for its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron®, a first-in-class Nav 1.7 inhibitor for treating chemotherapy-induced neuropathic pain (CINP). The drug has shown promising results in previous trials, demonstrating statistically significant reduction in cancer-related pain with an acceptable safety profile across over 700 patients, and importantly, shows no addiction potential.
The company is targeting a significant unmet medical need, as one-third of patients treated with certain chemotherapeutics develop chronic painful neuropathy, with no currently approved treatments. The CINP market is valued at approximately $1.5B, representing a substantial opportunity for Dogwood Therapeutics.
Dogwood Therapeutics (NASDAQ: DWTX) announced positive top-line data from their BHC IMC-2 Long-COVID study. The low-dose combination of valacyclovir 750 mg + celecoxib 200 mg twice daily showed clinically meaningful reductions in Long-COVID related fatigue and sleep disturbance compared to placebo. The higher dose (valacyclovir 1500 mg) was less effective due to GI adverse events. The study's results will inform the design of a planned Phase 2 study with approximately 200 participants. The company also has two other assets: Halneuron® in Phase 2b for chemotherapy-induced neuropathic pain and IMC-1 which is Phase 3-ready for fibromyalgia.
Dogwood Therapeutics (DWTX) announced Q3 2024 financial results following its formation in October through the combination of Virios Therapeutics and Pharmagesic Holdings. The company secured $19.5M in debt financing, with $16.5M funded and $3.0M expected in Q1 2025. Their pipeline includes Halneuron® for chemotherapy-induced neuropathic pain (Phase 2b), IMC-1 for fibromyalgia (Phase 3-ready), and IMC-2 for Long-COVID (Phase 2a). Q3 net loss was $2.3M ($2.05 per share) compared to $1.2M ($1.62 per share) in Q3 2023. Top-line results from the Long-COVID study are expected mid-November 2024.
Dogwood Therapeutics (Nasdaq: DWTX), a clinical-stage biopharmaceutical company formerly known as Virios Therapeutics, has announced it will release its Q3 2024 financial results on Thursday, November 7, 2024, before market open. The company will host a webcast and conference call at 8:30 a.m. ET on the same day, featuring management discussion of results and a corporate update. Investors can access the live call by dialing 888-506-0062 (domestic) or 973-528-0011 (international) using access code 838895, or view the webcast through the company's website under the Investors section.
Dogwood Therapeutics (DWTX) has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company, previously known as Virios Therapeutics, reported two significant developments: upcoming top-line results from the Bateman Horne Center's phase 2a study of IMC-2 for Long-COVID treatment, expected in mid-November 2024, and ongoing integration efforts following their recent acquisition of Pharmagesic Holdings in early October 2024.